文献速递心脏核医学肿瘤 PET/CT

18F标记亲脂性阳离子PET显像用于化疗所致急性心脏毒性

Imaging of Chemotherapy-Induced Acute Cardiotoxicity with 18F-Labeled Lipophilic Cations.
PubMed 文献 · J Nucl Med · 2019-05-30

本研究在大鼠离体灌注心脏和体内模型中评估18F-MitoPhos作为心脏显像剂,并与99mTc-sestamibi等亲脂性阳离子示踪剂比较。结果显示18F-MitoPhos心脏滞留量高,在阿霉素急性心脏毒性模型中呈剂量依赖性摄取下降,且早于其他生物标志物改变,提示其可用于化疗心脏毒性早期PET显像。

要点

  • 18F-MitoPhos在离体灌注大鼠心脏中滞留量是99mTc-sestamibi的两倍以上。
  • 阿霉素20 mg/kg组心脏平均SUV(30–60 min)从对照3.5±0.5降至1.8±0.1。
  • 心脏摄取下降出现在可检测生物标志物改变之前。

核心结论

  • 18F-MitoPhos药代动力学适合心脏显像,是化疗所致心脏毒性PET显像的有前景示踪剂。
  • 这是放射性标记亲脂性阳离子用于化疗心脏毒性PET显像的首次展示。

研究设计与样本

  • 研究在大鼠离体灌注心脏中比较18F-MitoPhos与99mTc-sestamibi的心脏摄取及对线粒体膜电位降低的反应。
  • 体内评估18F-MitoPhos与18F-fluorobenzyltriphenylphosphonium的基线药代动力学及对急性阿霉素心脏毒性的反应。
  • 阿霉素静脉给药剂量为10、15或20 mg/kg,给药48小时后评估。

主要发现

  • 离体灌注大鼠心脏中18F-MitoPhos心脏滞留量是99mTc-sestamibi的两倍以上。
  • 18F-MitoPhos体内60分钟心脏/组织比值:血浆304±186、肝脏11.2±1.2、肺3.8±0.6。
  • 阿霉素处理呈剂量依赖性心脏18F-MitoPhos滞留下降,30–60分钟平均心脏SUV从对照3.5±0.5降至20 mg/kg组1.8±0.1。
  • 其他评估的生物标志物未见改变。

关键数值与推荐

  • 阿霉素20 mg/kg组平均心脏SUV(30–60 min)为1.8±0.1,对照组为3.5±0.5。
  • 18F-MitoPhos 60分钟心脏/血浆比值304±186、心脏/肝脏11.2±1.2、心脏/肺3.8±0.6。

临床怎么用

  • 18F-MitoPhos PET有望在生物标志物可检测改变之前早期发现化疗所致心脏毒性。
  • 该示踪剂药代动力学适合心脏显像,可进一步临床转化评估。

局限性

  • 研究仅在大鼠模型中进行,尚未在人体验证。
  • 阿霉素模型为急性心脏毒性,未涵盖慢性或长期心脏毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many chemotherapy agents are toxic to the heart, such that increasing numbers of cancer survivors are now living with the potentially lethal cardiovascular consequences of their treatment. Earlier and more sensitive detection of chemotherapy-induced cardiotoxicity may allow improved treatment strategies and increase long-term survival. Lipophilic cation PET tracers may be suitable for early detection of cardiotoxicity. This study aimed to evaluate an 18F-labeled lipophilic phosphonium cation, [1-(2-18F-fluoroethyl),1H[1,2,3]triazole-4-ethylene]triphenylphosphonium bromide (18F-MitoPhos), as a cardiac imaging agent, comparing it with leading PET and SPECT lipophilic cationic tracers before further assessing its potential for imaging cardiotoxicity in an acute doxorubicin model. Methods: Cardiac uptake and response to decreased mitochondrial membrane potential of 18F-MitoPhos and 99mTc-sestamibi were tested in isolated perfused rat hearts. Baseline pharmacokinetic profiles of 18F-MitoPhos and 18F-fluorobenzyltriphenylphosphonium and their response to acute doxorubicin-induced cardiotoxicity were assessed in rats in vivo (10, 15, or 20 mg of doxorubicin per kilogram, intravenously, 48 h beforehand). Results: Cardiac retention of 18F-MitoPhos was more than double that of 99mTc-sestamibi in isolated perfused rat hearts. A favorable biodistribution of 18F-MitoPhos in vivo was observed, with heart-to-tissue ratios of 304 ± 186, 11.2 ± 1.2, and 3.8 ± 0.6 for plasma, liver, and lung, respectively (60 min). A significant dose-dependent loss of cardiac retention of 18F-MitoPhos was observed on doxorubicin treatment, with average cardiac SUV from 30 to 60 min (mean ± SD) decreasing from 3.5 ± 0.5 (control) to 1.8 ± 0.1 (doxorubicin, 20 mg/kg). Other assessed biomarkers showed no alterations. Conclusion:18F-MitoPhos showed pharmacokinetic parameters suitable for cardiac imaging. A significant dose response of cardiac uptake to doxorubicin treatment was observed before detectable biomarker alterations. 18F-MitoPhos is therefore a promising tracer for imaging chemotherapy-induced cardiotoxicity. To our knowledge, this is the first demonstration of radiolabeled lipophilic cations being used for the PET imaging of chemotherapy-induced cardiotoxicity and indicates the potential application of these compounds in this area.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. McCluskey SP, Haslop A, Coello C, et al. Imaging of Chemotherapy-Induced Acute Cardiotoxicity with 18F-Labeled Lipophilic Cations. J Nucl Med. 2019. PMID: 31147403. doi:10.2967/jnumed.119.226787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。